Status:
RECRUITING
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Acute Myeloid Leukemia
Genetic Predisposition to Disease
Eligibility:
All Genders
Up to 25 years
Brief Summary
Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms. T...
Eligibility Criteria
Inclusion
- 0-25 years old
- Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or
- Relapsed or refractory AML or
- Patients with genetic predisposition to develop AML or
- Patients without haematological malignancy nor AML genetic predisposition syndrome who undergo bone marrow aspirate as part of standard of care
- Signed informed consent of parents for patients aged less than 18 years old or signed informed consent of the patient for patients aged 18 and over.
Exclusion
- Refuse to participate
- Chronic myeloid leukemia (CML)
- Lack of health insurance (French social security)
- Under protection (tutelle, curatelle or sauvegarde de justice)
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
May 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2033
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05772559
Start Date
May 31 2023
End Date
May 31 2033
Last Update
June 26 2024
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens Picardie site Sud
Amiens, France
2
CHU Angers
Angers, France
3
Hopital Minjoz
Besançon, France
4
CHU Pellegrin
Bordeaux, France